Press Releases

Publication in Cephalalgia Indicates eNeura’s sTMS Significantly Reduces Migraine Frequency

ESPOUSE Study Central to FDA Clearance of sTMS for Migraine Prevention

Baltimore, MD – April 3, 2018 – eNeura, Inc., a privately held medical technology company, announced today the publication of a study in the peer-reviewed journal, Cephalalgia, demonstrating the company’s portable, Transcranial Magnetic Stimulation (sTMS) technology, significantly reduces the frequency of migraine headache following daily administration.  sTMS is the only treatment in the United States indicated both for the acute and prophylactic treatment of all types of migraine headache.

Read more

eNeura, Inc. Announces Series D Financing

Investment to fund commercialization of eNeura’s sTMS mini
for treatment and prevention of migraine

Baltimore, MD, February 6, 2018 – eNeura, Inc., a privately held medical technology company developing non-invasive, non-drug treatment and prevention of migraine headache, announced today that it had completed a Series D financing led by Camden Partners Nexus, an investment group based in Baltimore, Maryland.  The proceeds of the Series D financing will be used for the commercial expansion of the Company’s sTMS mini neuromodulation device for the acute treatment and prevention of migraine.

Read more

eNeura, Inc. Receives FDA Clearance for Use of SpringTMS® for Migraine Prevention

SpringTMS is the only product available to patients in the United States
for both acute treatment of migraine and migraine prevention.
eNeura to exhibit at the 18th Congress of the International Headache Society (IHC2017)

Baltimore, MD – September 7, 2017 – eNeura, Inc., a privately held medical technology company, announced today that it has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) that states:  “The eNeura Spring TMS is indicated for the acute and prophylactic treatment of migraine headache.”  With this FDA clearance the SpringTMS is the only product in the United States indicated both for the acute and prophylactic treatment of migraine headache. 

Read more

eNeura, Inc. Receives CE Mark Label Extension Expanding Use of SpringTMS® to Include Migraine Prevention

Baltimore, MD – April 21, 2016 – eNeura, Inc., a privately held medical technology company, announced today that it has obtained an expanded CE Marking in Europe extending the label for its SpringTMS® device to include migraine prevention. The label extension adds to the existing SpringTMS CE Marking for acute treatment of migraine and UK National Institute for Health and Care Excellence (NICE) guidance recommending single-pulse Transcranial Magnetic Stimulation (sTMS) for acute and preventative treatment of migraine.

Read more

eNeura Inc. Receives FDA Clearance for SpringTMS Migraine Treatment Device

Baltimore, MD – May 23, 2014 – eNeura, Inc., eNeura, Inc., a privately held medical technology company, announced today that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its SpringTMS® migraine treatment device. SpringTMS is the first medical device available to patients in the United States for the acute treatment of pain associated with migraine headache with aura.

Read more

eNeura Gets FDA Clearance for More Portable Migraine Treatment Device

Baltimore, MD – May 23, 2014 – eNeura, Inc., a privately held medical technology company, announced today that it has obtained an expanded CE Marking in Europe extending the label for its SpringTMS® device to include migraine prevention. The label extension adds to the existing SpringTMS CE Marking for acute treatment of migraine and UK National Institute for Health and Care Excellence (NICE) guidance recommending single-pulse Transcranial Magnetic Stimulation (sTMS) for acute and preventative treatment of migraine.

Read more

eNeura Files 510K with the FDA for SpringTMS Migraine Treatment

Sunnyvale, Calif. and Baltimore, MD – January 27, 2014 – eNeura Inc., a privately held medical technology company, announced today that it filed a 510(k) with the U.S. Food and Drug Administration (FDA) for the SpringTMS® transcranial magnetic stimulation (TMS) device. SpringTMS is a second-generation medical device based on eNeura’s ground-breaking CerenaTMS™, which recently received FDA clearance for the treatment of pain caused by migraine headaches preceded by an aura: a visual, sensory or motor disturbance immediately preceding the onset of a migraine attack. SpringTMS is more patient-friendly and portable compared to the previous generation device, and is already CE Marked in Europe and available by prescription in the UK.

Read more

eNeura’s SpringTMS Migraine Treatment Receives Positive NICE Guidance

Sunnyvale, Calif. – January 22, 2014 – eNeura Inc., a privately held medical technology company, announced today that the United Kingdom’s National Institute for Health and Care Excellence (NICE) has published interventional procedure guidance recommending Transcranial Magnetic Stimulation (TMS) for the treatment of migraine. The new guidelines are based on a thorough technology appraisal, which includes assessments for product safety and efficacy for routine use, and are designed to support the National Health Service (NHS) in the process of introducing new procedures in a responsible way.

Read more
Indication: The sTMS mini™ by eNeura® is indicated for the acute and prophylactic treatment of migraine headache.